Monica Ubach-Vila

Barcelona Biomedical Research Park
Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma.

Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma.

Journal: Biochemical pharmacology

Published: November 10, 2022

Neural crest-related NXPH1/α-NRXN signaling opposes neuroblastoma malignancy by inhibiting organotropic metastasis.

Neural crest-related NXPH1/α-NRXN signaling opposes neuroblastoma malignancy by inhibiting organotropic metastasis.

Journal: Oncogene

Published: March 15, 2022

MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment.

MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment.

Journal: BMC cancer

Published: October 11, 2021

SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas.

SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: August 04, 2021

Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas.

Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas.

Journal: The journal of pathology. Clinical research

Published: December 14, 2020

Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution.

Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: January 29, 2020

Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01.

Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01.

Journal: Science translational medicine

Published: June 13, 2018

The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma.

The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma.

Journal: Oncotarget

Published: March 24, 2018

Glucosylated nanomicelles target glucose-avid pediatric patient-derived sarcomas.

Glucosylated nanomicelles target glucose-avid pediatric patient-derived sarcomas.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: January 04, 2018

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.

Journal: Oncotarget

Published: July 05, 2017

Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier.

Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: May 31, 2017

Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.

Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: January 09, 2017

Showing 1-12 of 19

Last Updated: 09/26/2026